- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00699010
Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse
A Phase II, Single-Center, Randomized, Double-Blind Assessment of the Abuse Liability of Acurox (Oxycodone HCl and Niacin) Tablets in Subjects With a History of Opioid Abuse
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In the Treatment Phase, subjects randomly received oxycodone HCl 40 mg administered in combination with niacin 240 mg and oxycodone HCl 40 mg alone in crossover design. 15 subjects were randomized to receive oxycodone/niacin first followed by oxycodone with a 48 hour washout between doses. 15 subjects randomized to receive oxycodone before the oxycodone/naicin dose with a 48 hour washout between doses. The purpose of the Treatment Phase was to assess the abuse liability and abuse deterrence potential of 4 times the recommended 2-tablet dose of Acurox® Tablets 5/30 mg versus oxycodone HCl 40 mg alone (8 tablets per dose).
All 30 subjects received a single dose of each study treatment. Subjects were fasted prior to dosing on all dose days.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
- Johns Hopkins Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is male or female between 18 and 55 years of age
- Subject meets DSM-IV Criteria for the Diagnosis of Opioid Substance Abuse and subject is unlikely to experience an idiosyncratic reaction or respiratory depression after ingesting 40 mg of oxycodone
- Body weight is not more than 20% above or below ideal body weight
- Subject agrees to abstain from any Rx or OTC drugs (except as authorized by the Investigator) or alcohol
- Subject is in generally good health
- Subject is reliable, willing, cooperative, able to communicate effectively, and has a minimum of a 6th grade reading level
- Subject has an acceptable score on the MMSE for cognitive impairment
- For women of child-bearing potential: woman is not pregnant and not nursing, and is practicing an acceptable method of birth control
Exclusion Criteria:
- Subject has a disease that may endanger the subject or the validity of the data
- Subject is currently physically dependent on opiates or alcohol
- Subject was exposed to any investigational drug within 30 days prior to the inpatient phase
- Subject has a history of hypersensitivity to any drug, or a known allergy to any component of the study drug formulation
- Subject has a positive urine drug screen for a non-opiate drug
- Subject has a predisposing condition that may place the subject at risk for receiving niacin or oxycodone, or confound the study analyses
- Subject ingested niacin at doses higher than SDI within 14 days prior to the inpatient phase
- Subject has an abnormal bleeding tendency
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Acurox 5/30mg taken first
oxycodone HCl/Niacin 5/30mg tablets; 8 tablets per dose
|
followed by oxycodone 5mg with 48 hour washout
|
Active Comparator: Oxycodone 5mg taken first
oxycodone HCl 5mg tablets; 8 tablets per dose
|
followed by Acurox 5/30mg with 48 hour washout
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Drug Like/Dislike Effect at 30 Minutes Post Dose (E 30 Min)
Time Frame: Effects assessed at 0.5 hours after dosing.
|
"Do you dislike or like the drug effect you are feeling now?"
This question was rated on a 1 to 29 point VAS scale that was anchored in the center with "neither like nor dislike" (14), on the left with "dislike an awful lot" (1), and on the right with "like an awful lot" (29).
|
Effects assessed at 0.5 hours after dosing.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Donald R Jasinski, MD, Johns Hopkins Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AP-ADF-111
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid Abuse
-
Baylor College of MedicineChandrakantanWithdrawnOpioid Dependence | Opioid Use | Opioid Abuse, Unspecified
-
Bubba NicholsonTampa General Hospital; Otrimed Clinical ResearchUnknownOpioid-Related Disorders | Opioid Dependence | Opioid Use | Opioid Abuse | Opioid-use Disorder | Opioid Addiction | Opioid Intoxication | Opioid Abuse, Continuous Use | Paternal Pheromone Deficiency | Opioid Abuse, Episodic
-
Weill Medical College of Cornell UniversityThe Institute for Family Health; New York State Health FoundationCompletedOpioid-Related Disorders | Opioid Use | Opioid Abuse | Prescription Drug Abuse and DependencyUnited States
-
The University of Texas Health Science Center at...TerminatedOpioid Dependence | Opioid Abuse, UnspecifiedUnited States
-
Kaiser PermanenteNational Institute on Drug Abuse (NIDA)Active, not recruitingOpioid Use Disorder | Substance Use Disorders | Substance Abuse | Opioid Abuse | Drug Abuse | Drug Use Disorders | Cannabis Abuse | Cannabis-Related Disorder
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityUnknownOpioid Abuse or Dependence
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA)CompletedOpioid Abuse (Disorder)United States
-
Rutgers, The State University of New JerseyNational Institute on Drug Abuse (NIDA); University of UtahRecruitingTobacco Use | Opioid Use | Polysubstance AbuseUnited States
-
Wayne State UniversityHenry Ford Health SystemRecruitingOpioid Abuse | Benzodiazepine Abuse | Polysubstance AbuseUnited States
-
University of UtahNational Institute on Drug Abuse (NIDA); University of CincinnatiNot yet recruitingOpioid Abuse | Prescription Opioid AbuseUnited States
Clinical Trials on Acurox 5/30mg taken first
-
Acura Pharmaceuticals Inc.King Pharmaceuticals is now a wholly owned subsidiary of PfizerCompletedOpioid AbuseUnited States
-
Acura Pharmaceuticals Inc.CompletedOpioid-Related DisordersUnited States
-
Acura Pharmaceuticals Inc.Completed
-
Queen Mary University of LondonCompleted
-
St. Jude Children's Research HospitalNational Eye Institute (NEI)Completed
-
Centre Hospitalier Universitaire DijonCompleted
-
RxCelerate LtdRxCelerate LimitedUnknownMonoclonal Gammopathy of Unknown SignificanceUnited Kingdom
-
Centre Hospitalier Universitaire DijonCompletedLocalized Non-Resectable Adult Hepatocellular CarcinomaFrance
-
Hospices Civils de LyonRecruitingRare Diseases | Toxic Epidermal NecrolysesFrance
-
SK Chemicals Co., Ltd.CompletedDrug Interaction Potentiation